Investigation and Response to an Outbreak of Dengue: Island of Hawaii, 2015-2016.


Journal

Public health reports (Washington, D.C. : 1974)
ISSN: 1468-2877
Titre abrégé: Public Health Rep
Pays: United States
ID NLM: 9716844

Informations de publication

Date de publication:
Historique:
pubmed: 11 2 2020
medline: 6 5 2020
entrez: 11 2 2020
Statut: ppublish

Résumé

From September 2015 through March 2016, Hawaii had the largest outbreak of locally transmitted dengue since 1944. We report on the Hawaii Department of Health's (HDOH's) investigation, findings, and response to the outbreak. We defined cases of dengue using a modified version of the Council of State and Territorial Epidemiologists' case definition for dengue virus infections. We conducted epidemiologic investigations, including interviews with case-persons, review of medical records, laboratory testing, genetic sequencing of specimens, and geographic information system (GIS) data analysis. Outbreak response included community outreach and vector-control activities. We identified 264 confirmed cases of dengue; illness onset dates ranged from September 11, 2015, to March 17, 2016, all with reported travel to or residence on the Island of Hawaii. Of 264 persons with confirmed dengue, 238 (90.2%) were Hawaii residents. Thirty-seven (14.0%) persons required hospitalization; no cases of severe dengue or death were reported. GIS hot-spot analysis identified a cluster of cases on the western side of the island. Established risk factors for dengue exposure included holes in window or door screens, presence of standing water, and not using insect repellent or wearing protective clothing. To prevent or mitigate the spread of future arboviral introductions and outbreaks, the public health response should focus on behavioral and cultural attitudes, emphasizing personal mosquito protection and mosquito control at the community level. Outbreak responses can also be enhanced through the use of advanced GIS techniques, such as hot-spot analysis, to provide situational awareness and guide response efforts.

Identifiants

pubmed: 32040922
doi: 10.1177/0033354920904068
pmc: PMC7036608
doi:

Substances chimiques

Immunoglobulin M 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

230-237

Subventions

Organisme : NCEZID CDC HHS
ID : U50 CK000415
Pays : United States

Références

Prev Med Rep. 2018 Oct 31;12:336-342
pubmed: 30416953
Am J Public Health Nations Health. 1945 Mar;35(3):261-70
pubmed: 18016137
Emerg Infect Dis. 2005 May;11(5):742-9
pubmed: 15890132
J Am Mosq Control Assoc. 2013 Jun;29(2):154-63
pubmed: 23923330
Emerg Infect Dis. 2007 Mar;13(3):419-25
pubmed: 17552095
Emerg Infect Dis. 2005 Sep;11(9):1433-6
pubmed: 16229774
Clin Epidemiol. 2013 Aug 20;5:299-309
pubmed: 23990732
BMC Public Health. 2012 Jan 26;12:83
pubmed: 22276682
Am J Trop Med Hyg. 2007 Jun;76(6):1182-8
pubmed: 17556633
Emerg Infect Dis. 2010 Apr;16(4):716-8
pubmed: 20350397
PLoS Negl Trop Dis. 2013 Jul 11;7(7):e2311
pubmed: 23875046
Emerg Infect Dis. 2009 Apr;15(4):591-3
pubmed: 19331740

Auteurs

David I Johnston (DI)

Disease Outbreak Control Division, Hawaii State Department of Health, Honolulu, HI, USA.

Melissa A Viray (MA)

Disease Outbreak Control Division, Hawaii State Department of Health, Honolulu, HI, USA.

Jenny M Ushiroda (JM)

Disease Investigation Branch, Hawaii State Department of Health, Honolulu, HI, USA.

Hua He (H)

Disease Investigation Branch, Hawaii State Department of Health, Honolulu, HI, USA.

A Christian Whelen (AC)

State Laboratories Division, Hawaii State Department of Health, Honolulu, HI, USA.

Rebecca H Sciulli (RH)

State Laboratories Division, Hawaii State Department of Health, Honolulu, HI, USA.

Gail Y Kunimoto (GY)

Medical Microbiology Branch, State Laboratories Division, Hawaii State Department of Health, Honolulu, HI, USA.

Sarah Y Park (S)

Disease Outbreak Control Division, Hawaii State Department of Health, Honolulu, HI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH